In this video, Prof. Othman Al-Sawaf, hematologist and clinical investigator at the University Hospital Cologne and the German CLL Study Group, shares key findings from a randomized study comparing fixed-duration and continuous treatment strategies in previously untreated chronic lymphocytic leukemia (CLL).
He discusses how fixed-duration regimens with venetoclax-based combinations demonstrated non-inferiority to continuous ibrutinib in terms of progression-free survival, while also achieving deeper MRD-negative remissions. The conversation highlights the clinical relevance of time-limited therapy, subgroup insights including IGHV and TP53 status, and the importance of personalized treatment decisions in modern CLL care.
